RT Journal Article
SR Electronic
T1 Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.120.245290
DO 10.2967/jnumed.120.245290
A1 Dong-Yeon Kim
A1 Ayoung Pyo
A1 Misun Yun
A1 Ramar Thangam
A1 Sung-Hwan You
A1 Ying Zhang
A1 Ye-rim Jung
A1 Dinh-Huy Nguyen
A1 Akhil Venu
A1 Hyeon Sik Kim
A1 Mee Sun Yoon
A1 Yeongjin Hong
A1 Jung-Joon Min
YR 2021
UL http://jnm.snmjournals.org/content/early/2021/01/22/jnumed.120.245290.abstract
AB Surface-exposed calreticulin (ecto-CRT) is a well-known ‘eat-me’ signal exhibited by dying cells that contributes to their recognition and destruction by the immune system. We assessed the use of a CRT-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for the early prediction of treatment response. Methods: A synthetic CRT-specific peptide KLGFFKR (CRTpep) was labeled with fluorescein isothiocyanate or 18F and characteristics of ecto-CRT was evaluated in colon cancer cell line in vitro and in vivo. Results: In vitro flow cytometry, immunofluorescence staining, and in vivo micro positron emission tomography imaging results showed that CRTpep detected pre-apoptotic cells treated with immunogenic drugs or radiation, but not those treated with the non-immunogenic drug or a non-therapeutic dose of immunogenic drug. Conclusion: The present results indicate that the CRT-specific peptide would enable the prediction of therapeutic response, thereby facilitating early decisions regarding the continuation or discontinuation of immunogenic treatment.